C. Heran

发表

Effects of SQ 14,225, an orally active inhibitor of angiotensin-converting enzyme on blood pressure, heart rate and plasma renin activity of conscious normotensive dogs.

B. Rubin, R. Laffan, M. E. Goldberg, 1978, European journal of pharmacology.

Carbopol-mediated paracellular transport enhancement in Calu-3 cell layers.

D. Wall, Lianli Li, Ronald L. Smith, 2006, Journal of pharmaceutical sciences.

Leukotrienes cause mesenteric vasoconstriction and hemoconcentration in rats without activating thromboxane receptors.

M. Ogletree, W. Schumacher, C. Heran, 1989, Prostaglandins.

Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.

R. Bentley, D. Colussi, J. Bostwick, 2000, European journal of pharmacology.

Effect of Thromboxane Antagonism on Recanalization During Streptokinase-Induced Thrombolysis in Anesthetized Monkeys

W. Schumacher, C. Heran, Christopher L. Heran, 1989, Journal of cardiovascular pharmacology.

Sensitivity of experimental venous and arterial thrombosis and bleeding to ancrod-induced defibrinogenation.

W. Schumacher, T. Steinbacher, C. Heran, 1996, Thrombosis research.

Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa.

C. Dunwiddie, R. Bentley, A. Spada, 1999, Journal of cardiovascular pharmacology.

Magnitude of thromboxane receptor antagonism necessary for antithrombotic activity in monkeys.

M. Ogletree, D. Harris, W. Schumacher, 1989, The American journal of physiology.

Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.

M. Ogletree, W. Schumacher, T. Steinbacher, 1993, The Journal of pharmacology and experimental therapeutics.

Effects of Antithrombotic Drugs in a Rat Model of Aspirin-Insensitive Arterial Thrombosis

S. Durham, W. Schumacher, T. Steinbacher, 1993, Thrombosis and Haemostasis.

Effect of thromboxane receptor antagonists on venous thrombosis in rats.

W. Schumacher, C. Heran, 1989, Journal of Pharmacology and Experimental Therapeutics.

Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa.

D L Cheney, C. Dunwiddie, D. Cheney, 1998, Journal of medicinal chemistry.

Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.

W. Schumacher, T. Steinbacher, C. Heran, 1996, Journal of cardiovascular pharmacology.

Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.

C. Dunwiddie, D. Cheney, R. Bentley, 1999, Journal of medicinal chemistry.

The effect of anesthesia on the pharmacokinetics of sublingually administered verapamil in rabbits.

M. Hussain, D. Wall, Ronald L. Smith, 2003, Journal of pharmaceutical sciences.

pH-Dependent Dissolution in Vitro and Absorption in Vivo of Weakly Basic Drugs: Development of a Canine Model

Xujin Lu, Duxin Sun, M. Hussain, 2005, Pharmaceutical Research.

Rat nasal lavage biomarkers to assess preclinical irritation potential of nasal drug formulations and excipients.

M. Hussain, Ronald L. Smith, N. Mathias, 2009, Journal of pharmaceutical sciences.

Comparison of the acute and chronic hemodynamic effects of captopril and guanethidine in spontaneously hypertensive rats.

M. Antonaccio, C. Heran, R. A. Ferrone, 1980, Clinical and experimental hypertension.

A rabbit model for sublingual drug delivery: comparison with human pharmacokinetic studies of propranolol, verapamil and captopril.

Ronald L. Smith, N. Mathias, C. Heran, 2006, Journal of pharmaceutical sciences.

Protamine-induced pulmonary hypertension in heparinized monkeys and pigs is inhibited by the thromboxane receptor antagonist SQ 30,741.

M. Ogletree, W. Schumacher, C. Heran, 1990, Eicosanoids.

Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.

Daniel L Cheney, C. Dunwiddie, D. Cheney, 2002, Bioorganic & medicinal chemistry letters.